Akorn gets $21.5 million funding approval for Calcium-DTPA, Zinc-DTPA

By Jennifer Chiou

New York, Feb. 13 - Akorn, Inc. said it received U.S. government approval for $21.5 million in funding for Calcium-DTPA and Zinc-DTPA.

The Department of Health and Human Services authorized the capital on Feb. 9.

Under the contract, the Buffalo Grove, Ill., manufacturer and marketer of sterile specialty pharmaceuticals said it will deliver a combined 450,000 units of Ca-DTPA and Zn-DTPA to the U.S. government during the first quarter.

The company first announced the commercial item award on Dec. 30.

Akorn added it licensed Ca-DTPA and Zn-DTPA from Hameln Pharmaceuticals Gmbh in October 2004.

"With the cooperation of the Departments of Homeland Security and Health and Human Services, we achieved our objective: to provide and supply effective countermeasures to protect the United States civilian population in the event of a radiological or nuclear event," president and chief executive officer Arthur S. Przybyl said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.